A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
Inclusion Criteria:
Exclusion Criteria:
Asahi-shi, Chiba 289-2511, Japan
Kashiwa-shi, Chiba 277-8567, Japan
Asahikawa-shi, Hokkaido 070-8610, Japan
Kahoku-gun, Ishikawa-ken 920-0293, Japan
Iruma-gun, Saitama 350-0495, Japan